Therma Bright Inc. announced the submission of its Health Canada application for the smart-enabled AcuVidTM COVID-19 Rapid Antigen Saliva Test for Point-of-Care Use (PoC). The HC application includes all the updated data from the Company's U.S. Food and Drug Administration's Emergency Use Authorization (EUA) application. Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 CAD | 0.00% | 0.00% | -60.00% |
1st Jan change | Capi. | |
---|---|---|
-60.00% | 2.31M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- THRM Stock
- News Therma Bright Inc.
- Therma Bright Submits Health Canada Application for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for Point-of-Care